Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 84,797	$ 48,440	$ 189,514	$ 150,168
Revenue, % change	75.00%		26.00%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 21,598	33,118	$ 91,331	103,283
Revenue, % change	(35.00%)		(12.00%)
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,182	5,894	$ 17,259	20,208
Revenue, % change	(46.00%)		(15.00%)
Diagnostics [Member] | NonMolecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 18,416	27,224	$ 74,072	83,075
Revenue, % change	(32.00%)		(11.00%)
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 63,199	15,322	$ 98,183	46,885
Revenue, % change	312.00%		109.00%
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 38,784	5,495	$ 55,691	17,495
Revenue, % change	606.00%		218.00%
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 24,415	$ 9,827	$ 42,492	$ 29,390
Revenue, % change	148.00%		45.00%